389 related articles for article (PubMed ID: 32757473)
1. Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges.
Caponetti GC; Bagg A
Int J Lab Hematol; 2020 Dec; 42(6):671-684. PubMed ID: 32757473
[TBL] [Abstract][Full Text] [Related]
2. CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice.
DeZern AE; Malcovati L; Ebert BL
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():400-410. PubMed ID: 31099654
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis.
Osman A; Patel JL
Clin Chem; 2021 Aug; 67(8):1062-1070. PubMed ID: 34263288
[TBL] [Abstract][Full Text] [Related]
4. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
Ganguly BB; Banerjee D; Agarwal MB
Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
[TBL] [Abstract][Full Text] [Related]
5. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
Steensma DP; Bejar R; Jaiswal S; Lindsley RC; Sekeres MA; Hasserjian RP; Ebert BL
Blood; 2015 Jul; 126(1):9-16. PubMed ID: 25931582
[TBL] [Abstract][Full Text] [Related]
6. The genetic and molecular pathogenesis of myelodysplastic syndromes.
Shallis RM; Ahmad R; Zeidan AM
Eur J Haematol; 2018 Sep; 101(3):260-271. PubMed ID: 29742289
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and Pathogenesis of Myelodysplastic Syndrome.
Rotter LK; Shimony S; Ling K; Chen E; Shallis RM; Zeidan AM; Stahl M
Cancer J; 2023 May-Jun 01; 29(3):111-121. PubMed ID: 37195766
[TBL] [Abstract][Full Text] [Related]
8. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
9. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
Nakajima H
Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
[TBL] [Abstract][Full Text] [Related]
10. VEXAS: is it time to reshape the nosology of clonal hematopoiesis?
Sujobert P; Largeaud L; Jamilloux Y; Heiblig M; Kosmider O
Expert Rev Hematol; 2023; 16(7):495-499. PubMed ID: 37119011
[TBL] [Abstract][Full Text] [Related]
11. Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia-related changes: A single institution experience.
Gao L; Hyter S; Zhang D; Kelting S; Woodroof J; Abdallah AO; Yacoub A; McGuirk J; Abdelhakim H; Godwin AK; Cui W
Int J Lab Hematol; 2022 Aug; 44(4):738-749. PubMed ID: 35352484
[TBL] [Abstract][Full Text] [Related]
12. Uncoding the genetic heterogeneity of myelodysplastic syndrome.
Lindsley RC
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):447-452. PubMed ID: 29222292
[TBL] [Abstract][Full Text] [Related]
13. Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.
Kennedy JA; Ebert BL
J Clin Oncol; 2017 Mar; 35(9):968-974. PubMed ID: 28297619
[TBL] [Abstract][Full Text] [Related]
14. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
Naqvi K; Sasaki K; Montalban-Bravo G; Alfonso Pierola A; Yilmaz M; Short N; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Kanagal-Shamanna R; Patel K; Soltysiak KA; Kantarjian HM; Garcia-Manero G
Cancer; 2019 Jul; 125(13):2233-2241. PubMed ID: 30861111
[TBL] [Abstract][Full Text] [Related]
15. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP).
Malcovati L; Cazzola M
Hematology Am Soc Hematol Educ Program; 2015; 2015():299-307. PubMed ID: 26637737
[TBL] [Abstract][Full Text] [Related]
16. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
Steensma DP
Best Pract Res Clin Haematol; 2021 Dec; 34(4):101327. PubMed ID: 34865699
[TBL] [Abstract][Full Text] [Related]
17. Updates in cytogenetics and molecular markers in MDS.
Tiu RV; Visconte V; Traina F; Schwandt A; Maciejewski JP
Curr Hematol Malig Rep; 2011 Jun; 6(2):126-35. PubMed ID: 21340513
[TBL] [Abstract][Full Text] [Related]
18. A Lower Frequency of Spliceosome Mutations Distinguishes Clonal Cytopenias of Undetermined Significance From Low-Risk Myelodysplastic Syndromes, Despite Inherent Similarities in Genomic, Laboratory, and Clinical Features.
Ferrone CK; McNaughton AJM; Rashedi I; Ring B; Buckstein R; Tsui H; Rauh MJ
Mod Pathol; 2023 Mar; 36(3):100068. PubMed ID: 36788103
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lower-risk myelodysplastic syndrome.
Choi EJ; Cho YU; Hur EH; Park HS; Choi Y; Lee JH; Lee KH; Kim M; Hwang SH; Jang S; Park CJ; Seo EJ; Lee JH
Br J Haematol; 2022 Aug; 198(4):703-712. PubMed ID: 35612271
[TBL] [Abstract][Full Text] [Related]
20. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.
Zhang L; Padron E; Lancet J
Leuk Res; 2015 Jan; 39(1):6-17. PubMed ID: 25465125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]